Company / Current Assets
PharmaCyte Biotech, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$22.4M
FY2025
5-year range
$2.3M / $85.5M
FY2021-FY2025
Trend
-55.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $85M in FY2022 to $22M in FY2025.
Based on SEC 10-K filings.
$22M in FY2025 with a 5-year CAGR of +84.8%.
Declined from $68M to $22M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -36.0%
- 5-Year CAGR
- +84.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- PharmaCyte Biotech, Inc.'s current assets has declined for 3 consecutive years.
- 5-year CAGR of +84.8%, indicating consistent growth.
- In FY2025, current assets decreased 55.6% year-over-year.
- Peak current assets was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.4M | -55.6% |
| FY2024 | $50.4M | -26.0% |
| FY2023 | $68.1M | -20.3% |
| FY2022 | $85.5M | +3657.6% |
| FY2021 | $2.3M | +119.3% |
| FY2020 | $1.0M | +58.8% |
| FY2019 | $653.4K | -49.1% |
| FY2018 | $1.3M | -63.7% |
| FY2017 | $3.5M | +74.2% |
| FY2016 | $2.0M | -51.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026